Related Experiment Video
Updated: Jan 7, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Disrupted Vessels-Connected Voices: Why Patient Partnership and Cross-Disease Collaboration Are Essential for
Irina Kruetzner1, Freya Droege2, Simone Kesten3
1Working Group Biomedicine and Cellular Biomechanics, Unit of Molecular Biology, Department of Engineering and Natural Sciences, Campus Recklinghausen, Westphalian University of Applied Sciences Gelsenkirchen, Bocholt, Recklinghausen, August-Schmidt-Ring 10, 45665 Recklinghausen, Germany.
Patient partnerships and cross-disease research are key to advancing therapies for rare vascular diseases like hereditary haemorrhagic telangiectasia (HHT). Collaboration accelerates progress by sharing resources and insights across related conditions.
Area of Science:
- Biomedicine
- Vascular Biology
- Rare Diseases
Background:
- Rare vascular diseases, such as hereditary haemorrhagic telangiectasia (HHT), face challenges due to complex mechanisms, limited patient data, and fragmented research.
- Progress in understanding and treating HHT is hindered by these obstacles.
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Purpose of Health Records II
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Longitudinal Research
Case Studies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

